ATE444305T1 - Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen - Google Patents

Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen

Info

Publication number
ATE444305T1
ATE444305T1 AT04802607T AT04802607T ATE444305T1 AT E444305 T1 ATE444305 T1 AT E444305T1 AT 04802607 T AT04802607 T AT 04802607T AT 04802607 T AT04802607 T AT 04802607T AT E444305 T1 ATE444305 T1 AT E444305T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulations
nmb1125 protein
nmb1125
protein
formulations
Prior art date
Application number
AT04802607T
Other languages
English (en)
Inventor
Feyt Rolando Pajon
Nieto Gerardo Enrique Guillen
Garcia Gretel Sardinas
Nunez Lazaro Hiram Betancourt
Serra Lila Castellanos
Negrin Yasser Perera
Diaz Darien Garcia
Perez Olivia Niebla
Menendez Evelin Caballero
Blanco Sonia Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of ATE444305T1 publication Critical patent/ATE444305T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04802607T 2003-12-03 2004-12-02 Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen ATE444305T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20030285A CU23237A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
PCT/CU2004/000015 WO2005054281A2 (es) 2003-12-03 2004-12-02 Proteína nmb1125 y su uso en formulaciones farmaceuticas

Publications (1)

Publication Number Publication Date
ATE444305T1 true ATE444305T1 (de) 2009-10-15

Family

ID=40091628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04802607T ATE444305T1 (de) 2003-12-03 2004-12-02 Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen

Country Status (18)

Country Link
US (1) US7691971B2 (de)
EP (1) EP1693378B9 (de)
KR (1) KR20060123759A (de)
CN (1) CN1890260A (de)
AR (1) AR047263A1 (de)
AT (1) ATE444305T1 (de)
AU (1) AU2004294376A1 (de)
BR (1) BRPI0417309A (de)
CA (1) CA2547317A1 (de)
CU (1) CU23237A1 (de)
DE (1) DE602004023419D1 (de)
ES (1) ES2334138T3 (de)
NO (1) NO20063020L (de)
NZ (1) NZ547520A (de)
PL (1) PL1693378T3 (de)
RU (1) RU2336900C2 (de)
WO (1) WO2005054281A2 (de)
ZA (1) ZA200604556B (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
CN100379757C (zh) * 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
DK1185691T3 (da) 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9911692D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic combinations

Also Published As

Publication number Publication date
CU23237A1 (es) 2007-09-26
EP1693378B1 (de) 2009-09-30
US7691971B2 (en) 2010-04-06
AR047263A1 (es) 2006-01-11
KR20060123759A (ko) 2006-12-04
NZ547520A (en) 2009-07-31
EP1693378A2 (de) 2006-08-23
RU2006123434A (ru) 2008-01-10
RU2336900C2 (ru) 2008-10-27
WO2005054281A2 (es) 2005-06-16
US20070218000A1 (en) 2007-09-20
AU2004294376A1 (en) 2005-06-16
NO20063020L (no) 2006-09-01
ZA200604556B (en) 2007-03-28
BRPI0417309A (pt) 2007-09-11
CA2547317A1 (en) 2005-06-16
CN1890260A (zh) 2007-01-03
PL1693378T3 (pl) 2010-03-31
WO2005054281A3 (es) 2005-08-04
DE602004023419D1 (de) 2009-11-12
EP1693378B9 (de) 2010-05-19
ES2334138T3 (es) 2010-03-05

Similar Documents

Publication Publication Date Title
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
IS2504B (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
IL231296A0 (en) Genetic products differentially expressed in tumors and the use thereof
EP1513825A4 (de) Antituberkulöses arzneimittel: zusammensetzungen und verfahren
KR20050009999A (ko) 약제학적 제제
PL377854A1 (pl) Farmaceutyczne preparaty donosowe oraz sposoby ich stosowania
NO20055774D0 (no) Flytende stabiliserte proteinformuleringer i belagte farmasoytiske beholdere
DE602004027354D1 (de) SUBSTITUIERTE 8y-PYRIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ON- UND 8y-PYRIMIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ONDERIVATE UND DEREN VERWENDUNG BEI NEURODEGENERATIVEN KRANKHEITEN
IL163868A (en) Hemiasterlin derivatives and pharmaceutical compositions comprising them
ATE454891T1 (de) Geschmacksstoffhaltige arzneimittelformulierungen mit verbesserten pharmazeutischen eigenschaften
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
NO20042890L (no) Farmasoytiske preparater og fremgangsmate for fremstilling derav
DE602005011818D1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
ATE456573T1 (de) Nmb0928-protein und dessen verwendung in pharmazeutischen formulierungen
PL361364A1 (en) Peptide and pharmaceutical composition as well as their therapeutic applications
GB0317877D0 (en) Pharmaceutical combinations and formulations with improved stability
ITRM20020119A1 (it) Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
ATE444305T1 (de) Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen
DE60317719D1 (de) Kosmetische und pharmazeutische zusammensetzungen mit lycopin
GB0308317D0 (en) Pharmaceutical preparations and their use
SI1610820T2 (sl) Visokokoncentrirane formulacije protitelesa in proteinov
GB0409770D0 (en) Pharmaceutical preparations and their uses
GB0326759D0 (en) Pharmaceutical formulations and their preparation and use
GB0304362D0 (en) Amino pyrimidine compounds and their use in medicine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties